


National Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol.
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for Medicare, Medicaid, Medicaid managed care, and commercial managed care organizations across the nation from January 2018 through December 2018.

Key National Findings



Initial Commercial Rejection Rate

57%


Medicare: **35%**



Final Commercial Rejection Rate

38%

Medicare: **12%**



Total Final Rejections

88,503*



Total Claims

407,539*

**Totals include data from all plan types.*

Commercial rejections included high-risk patients who meet criteria for PCSK9 inhibitors.



Prior Statin Use

38%



Heart Attack or Stroke

37%



Cardiovascular Disease

35%



Familial Hypercholesterolemia

31%

Highest Rejection Rates by Plan

Of national health plans that received at least 3,000 claims for PCSK9 inhibitors, the following had **the highest rates of rejection**:

- Federal Employee Benefit Plan **76%**
- UnitedHealth Group **72%**
- Express Scripts **67%**
- CVS Health **54%**

The following table details claims data for managed care organizations across the country that received at least 3,000 claims for PCSK9 inhibitors.

Commercial Managed Care Organization	Rejection %	Total Claims	Rejections
Federal Employee Benefit Plan	76%	4,702	3,559
UnitedHealth Group	72%	9,357	6,739
Express Scripts	67%	8,141	5,479
CVS Health	54%	5,553	2,992
Tricare Military Health SVC Sys	44%	4,882	2,149
Anthem	43%	3,388	1,442

Data source: National data supplier; Commercial plans; January-December 2018



Institute for Patient Access

The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality health care.

